Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

ST Oh, EF Simonds, C Jones, MB Hale… - Blood, The Journal …, 2010 - ashpublications.org
ST Oh, EF Simonds, C Jones, MB Hale, Y Goltsev, KD Gibbs Jr, JD Merker, JL Zehnder
Blood, The Journal of the American Society of Hematology, 2010ashpublications.org
Dysregulated Janus kinase–signal transducer and activator of transcription (JAK-STAT)
signaling due to activation of tyrosine kinases is a common feature of myeloid malignancies.
Here we report the first human disease-related mutations in the adaptor protein LNK, a
negative regulator of JAK-STAT signaling, in 2 patients with JAK2 V617F–negative
myeloproliferative neoplasms (MPNs). One patient exhibited a 5 base-pair deletion and
missense mutation leading to a premature stop codon and loss of the pleckstrin homology …
Abstract
Dysregulated Janus kinase–signal transducer and activator of transcription (JAK-STAT) signaling due to activation of tyrosine kinases is a common feature of myeloid malignancies. Here we report the first human disease-related mutations in the adaptor protein LNK, a negative regulator of JAK-STAT signaling, in 2 patients with JAK2 V617F–negative myeloproliferative neoplasms (MPNs). One patient exhibited a 5 base-pair deletion and missense mutation leading to a premature stop codon and loss of the pleckstrin homology (PH) and Src homology 2 (SH2) domains. A second patient had a missense mutation (E208Q) in the PH domain. BaF3-MPL cells transduced with these LNK mutants displayed augmented and sustained thrombopoietin-dependent growth and signaling. Primary samples from MPN patients bearing LNK mutations exhibited aberrant JAK-STAT activation, and cytokine-responsive CD34+ early progenitors were abnormally abundant in both patients. These findings indicate that JAK-STAT activation due to loss of LNK negative feedback regulation is a novel mechanism of MPN pathogenesis.
ashpublications.org